Interleukin therapy for Myocardial Infarction: IL-17 (Interleukin-17) improves myocardial function after myocardial infarction via up-regulation of PNUTS, 07/November/2016, 9. 49 pm

Natural product therapy for N-Myc-overexpressing tumors: Isorhapontigenin, isolated from Aiphanes Aculeata, and Norway/Sitka/White Spruce, increases the levels of tumor suppressor proteins TAp73, TAp63 and Fbw7, inhibits the expression of pro-survival proteins N-Myc, Cyclin-E and Mcl-1, and stalls the progression of c-Myc-overexpressing cancers via down regulation of its target gene, 7/November/2015, 3.52 pm
November 7, 2016
Natural product therapy for Bone disorders: Leonurus sibiricus L. extract inhibits the expression of Tgif2 and suppresses osteoporosis and bone metastasis via up-regulation of its target gene, 7/November/2016, 10.03 pm
November 7, 2016
Show all

What they say: 

A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published in the 7 March  2013 issue of Nature  by Prof Dimmler, Boon, and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Interleukin therapy for Myocardial Infarction: IL-17 (Interleukin-17) improves myocardial function after myocardial infarction via  up-regulation of PNUTS


Significance:

Given that: (1)  cardiovascular disease is the leading cause of death worldwide; (2) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; and (3) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars, there is an urgent need to find: (i)  a way to induce regeneration of adult cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs; and (iii) a side-effect-free drug.


From Research Findings to Therapeutic Opportunity: 

This study suggests a natural product-based cardiac regeneration therapy. IL-17, by increasing the expression of its target gene, it may increase the expression of PNUTS. Thereby, it may: (1) inhibit DNA damage responses, (2) inhibit telomere shortening; and (3) promote cardiomyocyte survival/regeneration.

Thus, by treating myocardial patients with IL-17, one may prevent ageing-associated (or, stress-associated) decline in cardiac function. Together, this study suggests that pharmacological formulations encompassing IL-17 activators”  may be used to improve cardiac function after myocardial infarction.  


Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Web:http://genomediscovery.org or http://newbioideas.com

To citeBoominathan, L.,  Interleukin therapy for Myocardial Infarction: IL-17 (Interleukin-17) improves myocardial function after myocardial infarction via  up-regulation of PNUTS, 07/November/2016, 9. 49 pm,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org


Undisclosed information: How  IL-17 (Interleukin-17)  increases the expression of PNUTS

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $300#

Results guaranteed if not refunded

# Research cooperation

Comments are closed.